Rapid Generation of Sustainable HER2-specific T-cell Immunity in Patients with HER2 Breast Cancer using a Degenerate HLA Class II Epitope Vaccine.
Knutson KL, Block MS, Norton N, Erskine CL, Hobday TJ, Dietz AB, Padley D, Gustafson MP, Puglisi-Knutson D, Mangskau TK, Chumsri S, Dueck AC, Karyampudi L, Wilson G, Degnim AC.
Knutson KL, et al.
Clin Cancer Res. 2020 Mar 1;26(5):1045-1053. doi: 10.1158/1078-0432.CCR-19-2123. Epub 2019 Nov 22.
Clin Cancer Res. 2020.
PMID: 31757875
Free PMC article.
Clinical Trial.